Evidence review
How the WeighScore Is Calculated
The six weighted dimensions behind every GLP-1 Scorecard grade, how they roll up to a 0–100 WeighScore, and what never moves the number.
On this page
The WeighScore is a weighted sum of six recorded editorial marks. Below are the weights and calculation. Reproducing that arithmetic does not establish that each mark reflects current prices, care or service performance. If you would rather see it as a reference table, the full methodology lays out every weight side by side.
One formula, every provider
Each graded program has six editorial factor marks and the same weighted arithmetic. That makes the calculation reproducible; it does not mean every underlying fact has the same age or depth of verification. Some marks reflect earlier assessments, while newer reviews have more detailed public-source research. Historical and pharmacy-only profiles are not current program recommendations.
The six dimensions and their weights
Cost value — 25%. This is an editorial assessment of listed prices and payment conditions. Earlier marks use starting-price comparisons and recorded terms, not a verified equivalent-maintenance-dose calculation for every provider. Read the actual offer alongside the mark: medication inclusion, dose, renewal price and prepayment can change the comparison. Our six-month cost guide walks through those differences. Pepti now has a graded profile; its separate August investigation records historical findings rather than its current grading status.
Dose and formulation — 20%. Breadth of molecules, titration flexibility, and route options. This matters because the molecules are not interchangeable: once-weekly semaglutide 2.4 mg produced a mean −14.9% body-weight change in the STEP-1 trial1, while tirzepatide reached up to about −20.9% in SURMOUNT-12. Availability of more products does not establish better care, and trial results for approved formulations do not establish equivalent outcomes from compounded products. We unpack the trade-off in semaglutide vs. tirzepatide.
Clinical oversight — 20%. Prescriber model, provider verification confidence, and how care is supervised and escalated. This editorial mark is not a clinical safety evaluation or independent verification of every professional. For background on why the prescriber relationship matters, see what else GLP-1 drugs do, beyond weight loss for research on outcomes beyond weight loss.
Labs and monitoring — 15%. Whether baseline labs, ongoing check-ins, and side-effect monitoring are included or sold as extras — including whether a provider tracks body composition, not just the scale, since a real share of GLP-1 weight loss is lean mass; see does semaglutide or tirzepatide cause muscle loss? Our guide to GLP-1s and alcohol examines that separate area of evidence.
Fulfillment — 12%. Pharmacy sourcing transparency, shipping reliability, and cold-chain handling — including whether a provider will tell you which pharmacy fills your prescription.
Contract terms — 8%. Cancellation friction, refund posture, auto-renewal honesty, and lock-in. A smaller weight can still involve a consequential buying decision. Our dated Rehydra+ investigation illustrates why a monthly-equivalent headline and the total commitment need separate attention; consult the current review for later recorded terms.
How the dimensions become one number
The calculation multiplies each recorded 0–100 mark by its weight and adds the six results. The weights total 100%. An equal-sized change in cost value moves the total more than one in contract terms. That arithmetic does not validate how the input marks were assigned.
From score to letter grade
The WeighScore maps to a letter: A (93+), A− (90–92.9), B+ (87–89.9), B (83–86.9), B− (80–82.9), C+ (77–79.9), and C (below 77). A grade summarizes the recorded editorial factor marks. It is not a safety rating or medical advice. A high grade does not guarantee that the current offer or care is right for you.
What never moves the number
Affiliate relationships. A provider that pays us a commission runs through the exact same rubric as one that does not, and a weak provider is graded low regardless of any partnership. The scoring function has no input for who pays; it can only read the six factor marks. Nor does the write-up soften — an unflattering finding about a provider we earn from stays in, and where the evidence behind a claim is thin we say so. The full detail lives in our disclosure, the reference weights in the methodology, and the standing rules we hold every write-up to in our editorial policy — which also names who we are and how this site makes money.
Facts change; the formula does not
Provider pricing, medication menus and terms change. A factual correction can reach a review before all six factor marks are reassessed, so a revision date is not a promise of a complete regrade or fresh verification of every statement. The formula stays fixed, but the quality of a comparison also depends on the evidence behind its inputs.
Use the recommendation, sources and stated limitations alongside the number. Our research library provides practical context, and the provider reviews show the underlying marks. The graded tirzepatide ranking prints each factor's contribution; comparisons put recorded provider facts side by side.
Frequently asked questions
What is the WeighScore?
A 0–100 grade assembled from six weighted dimensions — cost value (25%), dose and formulation (20%), clinical oversight (20%), labs and monitoring (15%), fulfillment (12%), and contract terms (8%) — then mapped to a letter grade. The same formula runs against every provider.
Do affiliate partnerships change a provider's WeighScore?
No. Every provider runs through the identical rubric, and a weak provider is graded low regardless of any commercial relationship. The score is computed from the six factor marks and has no input for who pays.
Is a high WeighScore a safety rating?
No. A grade is a relative read on how a provider compares in today's market, not a safety rating or medical advice. A licensed clinician should make decisions about your care.
References
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity.. New England Journal of Medicine. PubMed · PMID 33567185
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity.. New England Journal of Medicine. PubMed · PMID 35658024
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Continue reading
What Compounded GLP-1 Costs Per Month — and Why the Number Moves
Compare compounded GLP-1 quotes by dose, mandatory fees, billing dates and upfront commitment—and know when a monthly headline leaves the total unresolved.
ReadDoes Insurance Cover GLP-1 Weight-Loss Drugs?
Why GLP-1 insurance coverage is so inconsistent, the actual law behind the weight-loss exclusion, and what real-world data shows happens when coverage lapses.
ReadA GLP-1 Recall or Counterfeit Alert: Check the Exact Product
Match a dated GLP-1 alert to the exact product. Read the full notice and its exceptions; a lot number alone cannot authenticate a package.
ReadGLP-1 Side Effects: What the Trials and FDA Labels Actually Report
The real side-effect data behind semaglutide and tirzepatide — GI rates, the boxed warning, gallbladder risk, retinopathy, and compounded-dosing errors.
ReadLiraglutide vs. Semaglutide: Daily or Weekly?
Compare daily liraglutide with weekly semaglutide injections: STEP 8 results, treatment burden, product differences and the questions behind a price quote.
ReadMEDVi Review: Read the Renewal and Refund Terms Before Enrolling
MEDVi's brand membership excludes medication, cancellation needs 72 hours, and refund documents conflict. Our sourced October 2026 review, without a grade.
Read